Survivors of childhood cancer face a unique set of long-term challenges stemming from their early diagnosis and treatment interventions. These effects often emerge years after the initial cure, encompassing physical pain, cognitive impairments, fatigue, and social difficulties. Clinicians struggle to pinpoint which patients experience symptom severity intense enough to warrant extra intervention, largely because comprehensive symptom information is buried within lengthy transcript data from conversations and open-ended survey questions. Current clinical constraints prevent efficient manual analysis, highlighting an urgent need for advanced solutions.

St. Jude’s multidisciplinary team leveraged state-of-the-art large language models such as ChatGPT and Llama to test whether these AI systems could replicate or augment human expert analyses. They collected detailed interview data from a cohort of 30 survivors aged 8 to 17 and their caregivers, annotating over 800 discrete symptom-related data points across domains of severity and functional impact. Parallel analyses with expert human reviewers established a gold standard against which AI outputs were benchmarked.

Central to the investigation was the concept of “prompting”—the method by which AI models are instructed to perform a given task. Researchers contrasted four prompting strategies, bifurcated into simple and complex categories. Simple approaches, including zero-shot prompting where the AI receives no example guidance, and few-shot prompting which provides minimal exemplars, produced erratic and unreliable symptom recognition despite their ease of deployment. These methods failed to consistently grasp the contextual subtleties embedded in the survivor-caregiver dialogues.

Conversely, two advanced prompting strategies—chain-of-thought prompting and generated knowledge prompting—demonstrated superior performance. Chain-of-thought involves sequential, logical reasoning embedded into the AI’s instructions, enabling stepwise symptom interpretation. Generated knowledge prompting first instructs the AI to create relevant background context from available data before analyzing transcripts. Both methods exhibited a keen ability to distinguish between physical and cognitive symptom impacts, though their detection sensitivity for social effects showed moderate success.

This layered analytical approach illustrates the promise of embedding domain knowledge and reasoning steps into AI prompting, thereby aligning machine output more closely with nuanced human judgment in clinical settings. While still in exploratory stages, the findings build a robust conceptual framework for integrating AI-driven conversational analysis into real-time clinical decision-making processes. Such integration could substantially alleviate physician workload and enhance patient-tailored care delivery.

“Patients spend upwards of half their clinical encounters describing symptoms and related experiences,” explained I-Chan Huang, PhD, corresponding author and epidemiologist at St. Jude. “Our research confirms that large language models, equipped with sophisticated prompting, can unlock otherwise underutilized conversational data, providing meaningful insights into symptom severity and functional impact that assist physicians in delivering more precise care.”

The implications of this study extend beyond childhood cancer survivorship. The methodology offers a scalable, replicable blueprint for using AI to decode complex clinical narratives across diverse medical domains where symptom assessment relies heavily on subjective reporting and qualitative data. Enhanced AI interpretative capabilities could also accelerate patient monitoring and identify emergent health issues earlier in the disease trajectory.

Despite impressive early results, the research team cautions that extensive validation across larger and more varied patient populations remains imperative. The nuanced nature of social symptom impacts, in particular, warrants further refinement of AI prompting techniques and model architecture to deepen understanding. Ongoing collaborations between AI experts, clinicians, and survivors will be essential to optimize these tools for frontline use.

Funding for this endeavor stemmed from prominent sources including the National Cancer Institute’s multiple grant programs and the American Lebanese Syrian Associated Charities (ALSAC), ensuring sustained investment in childhood cancer research innovation. The collaborative team included experts from St. Jude, Wake Forest University School of Medicine, University of Memphis, Hallym University, and Stanford University Medical School, underscoring the multidisciplinary nature of this advancement.

This pioneering work illuminates the untapped potential of AI-enhanced conversational data analysis to revolutionize survivorship care. With continued refinement, large language models combined with advanced prompting strategies stand to become invaluable aids in ensuring that childhood cancer survivors receive the targeted interventions necessary for long-term health and quality of life.

By embracing these cutting-edge AI methodologies, the medical community moves closer to a future in which complex patient narratives are no longer an analytical bottleneck but a rich resource driving efficient, personalized healthcare. St. Jude Children’s Research Hospital continues to lead this charge, steering the intersection of pediatric oncology and artificial intelligence toward transformative clinical impact.

Subject of Research: Use of large language models and advanced prompting strategies for symptom detection in childhood cancer survivorship care
Article Title: Artificial Intelligence Unlocks Hidden Insights in Childhood Cancer Survivorship Care
News Publication Date: March 25, 2026
Web References: https://doi.org/10.1038/s43856-026-01499-5
References: Communications Medicine, 2026 publication by St. Jude Children’s Research Hospital researchers
Image Credits: St. Jude Children’s Research Hospital

At the forefront of this research is Dr. Yue Liao, an assistant professor of kinesiology at UTA and director of the Physical Activity and Wearable Sensors Lab. Dr. Liao’s expertise lies in leveraging mobile technology and wearable devices to continuously monitor physiological and behavioral data, providing a dynamic window into health patterns that traditional clinical visits fail to capture. Unlike sporadic, episodic measurements, wearable sensors facilitate real-time monitoring of critical variables such as blood glucose fluctuations, cardiovascular parameters, sleep cycles, and even behavioral states like mood and activity levels. Capturing these data over extended periods enables researchers to identify subtle trends and emerging signs of disease that could otherwise go unnoticed.

The central innovation of this study is the integration of continuous biometric data into the assessment of diabetes risk among childhood cancer survivors. Conventional risk assessment models, which rely on infrequent and static measurements taken during clinical appointments, are insufficient to account for the unique metabolic trajectories of these survivors, who often experience complex long-term physiological alterations. Wearable sensors allow scientists and clinicians to observe glucose variability—how blood sugar levels fluctuate throughout the day—in conjunction with behavioral patterns such as physical activity and sleep quality. These insights provide a far richer, multidimensional profile of individual health risks, potentially unveiling novel biomarkers and predictors of diabetes progression.

One critical challenge that the research addresses is the heterogeneity in survivorship trajectories among childhood cancer survivors. Unlike adult patients, who typically have a shorter window for developing age-related diseases, children who survive cancer have an extended lifespan, during which the cumulative effects of cancer treatments manifest as accelerated aging processes and increased susceptibility to metabolic and cardiovascular diseases. This necessitates the development of tailored, long-term monitoring and intervention strategies that not only reflect the unique biology of survivorship but also adapt to evolving lifestyle behaviors over the decades.

Furthermore, wearable devices are ideally suited to engage younger survivors in proactive health management. These individuals, having grown up in an era of ubiquitous technology, are generally more receptive to digital health platforms that integrate seamlessly with their daily routine. The challenge now is to harness this existing technology engagement while ensuring data privacy, accuracy, and clinical relevance. Responsible data stewardship and ethical use of the vast streams of biometric information generated are essential to transforming these tools from mere trackers into powerful instruments for disease prevention and health promotion.

Dr. Liao’s approach emphasizes two pivotal components: the supplementation of traditional clinical metrics with wearable sensor data and the redefinition of diabetes risk paradigms specifically for childhood cancer survivors. By weaving together real-time physiological data with behavioral markers, the research proposes a framework that not only detects early warning signs more effectively but also tailors interventions to individual risk profiles. This represents a shift from reactive medical care to anticipatory, personalized management aimed at mitigating disease onset.

The Physical Activity and Wearable Sensors Lab at UTA is at the cutting edge of this technological frontier. Its work encompasses monitoring daily behaviors such as exercise, diet, and sleep using mobile accelerometers, photoplethysmography, and continuous glucose monitors. Such multidimensional data collection facilitates the exploration of complex interactions between lifestyle factors and disease risk, enhancing both the precision and efficacy of health interventions.

Dr. Liao’s prior experience includes a postdoctoral fellowship and instructional role at the University of Texas MD Anderson Cancer Center, where she contributed to innovative oncological research from 2015 to 2020. This background enriches her current studies, enabling an insightful fusion of cancer biology, epidemiology, and wearable technology. Her work highlights the importance of interdisciplinary collaboration to tackle the multifaceted challenges inherent in survivorship care.

The implications of this research extend well beyond childhood cancer survivors. The principles underlying the use of wearable devices to capture continuous health data have applications across populations at risk for chronic diseases—essentially redefining preventive medicine. By enabling a granular, personalized view of health metrics, digital health technologies promise a paradigm shift in how we detect, monitor, and ultimately intervene in disease processes before they escalate into debilitating conditions.

One particularly compelling aspect of this research is the potential to uncover previously unrecognized risk indicators through pattern recognition and machine learning applied to wearable sensor datasets. This could herald a new era of predictive analytics in medicine, where algorithm-driven insights complement clinical expertise, paving the way for precision interventions tailored not only to disease profiles but also to behavioral and environmental contexts.

Nevertheless, the broad adoption of wearable health technology faces technical and ethical hurdles, including ensuring the accuracy and reliability of sensors, managing large-scale data integration, and addressing privacy concerns. Dr. Liao acknowledges these challenges and advocates for a balanced approach that aligns innovation with responsible data governance. Success in this arena requires collaboration among biomedical engineers, clinicians, data scientists, ethicists, and patients alike.

This groundbreaking work marks a significant milestone in the evolving field of digital health for oncology survivorship. By harnessing the power of wearable sensors to capture continuous health data, researchers are opening new avenues to mitigate the profound burden of chronic diseases in childhood cancer survivors. As this technology matures and integrates into clinical practice, it promises not only to improve long-term health outcomes but also to empower survivors with personalized tools for managing their wellbeing throughout their extended lifespans.

Subject of Research:
Health monitoring and diabetes risk assessment in childhood cancer survivors using wearable digital health devices.

Article Title:
The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk

News Publication Date:
15-Jul-2025

Web References:
http://dx.doi.org/10.1002/cncr.35977

Image Credits:
UTA

Keywords:
Wearable devices, Electronic devices, Diseases and disorders, Cancer, Health and medicine, Diabetes